On Monday,

周一，

Eli Lilly And Co

礼来公司

LLY

LLY

agreed to acquire

同意收购

Scorpion Therapeutics, Inc’s

蝎子治疗公司

PI3Kα inhibitor

PI3Kα抑制剂

program STX-478

程序STX-478

.

.

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.

STX-478是一种每日一次的口服突变选择性PI3Kα抑制剂，目前正在乳腺癌和其他晚期实体瘤的1/2期临床试验中进行评估。

Additionally, as part of the transaction, the privately-held Scorpion will spin out a new entity to hold its employees and non-PI3Kα pipeline assets.

此外，作为交易的一部分，私人控股的Scorpion将分拆出一个新实体，以持有其员工和非PI3Kα管道资产。

Also Read:

另请阅读：

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

肥胖治疗、并购活动将在即将到来的JPM医疗保健会议上占据中心地位

The new, independent company would be owned by Scorpion’s current shareholders, with Lilly holding a minority equity interest.

。

The new company will be led by members of the current Scorpion management team.

新公司将由现任Scorpion管理团队的成员领导。

The Financial Times report

《金融时报》报道

added

已添加

the proposed deal is a part of Eli Lilly’s strategy to reinvest profits from its successful diabetes and obesity drugs, Mounjaro and Zepbound, into expanding its drug pipeline.

拟议的交易是礼来公司将其成功的糖尿病和肥胖症药物Mounjaro和Zepbound的利润再投资于扩大其药物渠道的战略的一部分。

Under the terms of the agreement, Lilly will acquire Scorpion, and Scorpion shareholders could receive up to $2.5 billion in cash. Up to $1 billion will be paid upfront, with an additional $1.5 billion contingent on meeting specific performance milestones.

根据协议条款，礼来将收购Scorpion，Scorpion股东可获得高达25亿美元的现金。高达10亿美元的预付款将被支付，另外15亿美元取决于能否达到特定的绩效里程碑。

Price Action:

价格行动：

Eli Lilly stock is down 1.55% at $787.49 at last check Monday.

礼来公司股价周一最后一次下跌1.55%，至787.49美元。

Read Next:

阅读下一页：

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

为什么专注于抑郁症的Sage Therapeutics股价周一飙升？

Image: Shutterstock

图片：Shutterstock

LLY

LLY

Eli Lilly and Co

礼来公司。

$784.78

$784.78

-1.89

-1.89

%

%

Overview Rating:

概述评级：

Speculative

推测性

37.5%

37.5%

Technicals Analysis

技术分析

66

66

0

0

100

100

Financials Analysis

财务分析

20

20

0

0

100

100

Watchlist

观察名单

Overview

概述

Market News and Data brought to you by Benzinga APIs

Benzinga API为您带来的市场新闻和数据

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

©2025 Benzinga.com。Benzinga不提供投资建议。。